TriSalus Life Sciences, Inc. cotiza a 4.14 USD y tiene una capitalización bursátil de $255M. En los últimos 12 meses ha facturado $45M con un margen de flujo de caja libre del -41.9%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infus…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-11 |
|---|---|---|---|---|
| Real | — | $-0.16 | $-0.05 | $-0.87 |
| Estimado | $-0.10 | $-0.15 | $-0.13 | $-0.16 |
| Sorpresa | — | -6.7% | +61.5% | -443.8% |
| Métrica | TLSI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 84.6% | 57.0% | +27.5% |
| Operating Margin | -59.7% | -38.6% | -21.1% |
| Net Margin | -86.9% | -33.6% | -53.3% |
| FCF Margin | -41.9% | -13.9% | -28.1% |
| ROE | — | -40.4% | — |
| ROA | -111.0% | -32.0% | -79.0% |
| Current Ratio | 2.80 | 2.84 | -0.04 |
| Debt / Equity | -0.98 | 0.28 | -1.26 |